BJDX (Bluejay Diagnostics) Moat Score: 2/10 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJDX Bluejay Diagnostics Inc BJDX
35 GF Score
Price $1.16
View Full Analysis

What is Bluejay Diagnostics Moat Score?

Bluejay Diagnostics BJDX -6.07% 35 Moat Score is 2 as of Jul. 21, 2026. GuruFocus rates BJDX with a GF Score™ of 35/100. Among 841 Medical Devices & Instruments companies, Bluejay Diagnostics ranks better than 68.25% on this metric.

Bluejay Diagnostics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Bluejay Diagnostics has No Moat: Bluejay Diagnostics has very weak competitive advantages. It lacks significant market leadership, brand strength, or intellectual property that could provide a durable moat. The company operates in a highly competitive and rapidly evolving industry with limited pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bluejay Diagnostics might have No Moat - Very weak/transient advantages.

Bluejay Diagnostics  (NAS:BJDX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bluejay Diagnostics Moat Score Related Terms

BJDX vs ALURD, VTAK, AMIX: Moat Score Comparison

For the Medical Devices subindustry, Bluejay Diagnostics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bluejay Diagnostics Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's Moat Score distribution charts can be found below:

* The bar in red indicates where Bluejay Diagnostics's Moat Score falls into.


BJDX
35GF Score
Bluejay Diagnostics Inc BJDX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Bluejay Diagnostics (BJDX) has a Moat Score of 2 as of Jul. 21, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Bluejay Diagnostics ranks #267 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 31.7%.
Is Bluejay Diagnostics' Moat Score too high?
Bluejay Diagnostics' current Moat Score is 2. Based on the distribution chart, Bluejay Diagnostics ranks #267 out of 841 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bluejay Diagnostics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' Moat Score compare to ALURD and VTAK?
According to the Medical Devices & Instruments industry distribution chart, Bluejay Diagnostics ranks #267 out of 841 companies for Moat Score. This puts Bluejay Diagnostics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Bluejay Diagnostics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current Moat Score of 2. The current Moat Score is 2. Bluejay Diagnostics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current Moat Score is 2 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bluejay Diagnostics Business Description

Address 360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
35GF Score

Get the complete analysis for BJDX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.16
Price